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Abstract The likelihood of oral exposure to
nanoparticles (NPs) is increasing, and it is necessary
to evaluate the oral bioavailability of NPs. In vitro
approaches could help reducing animal studies, but
validation against in vivo studies is essential. Previ-
ously, we assessed the translocation of 50 nm poly-
styrene NPs of different charges (neutral, positive and
negative) using a Caco-2/HT29-MTX in vitro intesti-
nal translocation model. The NPs translocated in a
surface charge-dependent manner. The present study
aimed to validate this in vitro intestinal model by an
in vivo study. For this, rats were orally exposed to a
single dose of these polystyrene NPs and the uptake in
organs was determined. A negatively charged NP was
taken up more than other NPs, with the highest
amounts in kidney (37.4 lg/g tissue), heart (52.8 lg/g
tissue), stomach wall (98.3 lg/g tissue) and small
intestinal wall (94.4 lg/g tissue). This partly confirms
our in vitro findings, where the same NPs translocated
to the highest extent. The estimated bioavailability of
different types of NPs ranged from 0.2 to 1.7 %
in vivo, which was much lower than in vitro
(1.6–12.3 %). Therefore, the integrated in vitro model
cannot be used for a direct prediction of the bioavail-
ability of orally administered NPs. However, the
model can be used for prioritizing NPs before further
in vivo testing for risk assessment.
Keywords Polystyrene nanoparticles  Surface
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Introduction
The number and range of consumer products contain-
ing nanoparticles (NPs) is constantly growing, exam-
ples ranging from e.g. lipsticks, toothpaste, food
additives, health supplements and juice clarifiers to
food packaging materials (Chaudhry et al. 2008; PEN
2013, Bouwmeester et al. 2014). Therefore, the
likelihood of oral exposure to NPs is still increasing.
Thus, there is a need to develop methods to assess the
oral bioavailability of NPs. For scientific, ethical and
economical reasons, in vitro models are desired.
To assess the performance of in vitro models, NPs
need to be selected that differ in translocation
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efficiency. In several studies, polystyrene NPs (PS-
NPs) have been shown to translocate across in vitro
intestinal barrier models (Walczak et al. 2014;
Kulkarni and Feng 2013; Martinez-Argudo et al.
2007), and this translocation depended on NP charac-
teristics like size, charge and surface chemistry. In
addition, in vivo studies have demonstrated the
bioavailability of PS-NPs after oral exposure as well
(Jani et al. 1989, 1990; Hussain et al. 1997). However,
no data are available from studies that used the same
PS-NPs in vitro and in vivo. With the present in vivo
study, we aim to evaluate the validity of our in vitro
model by comparing the newly obtained data with the
previously obtained in vitro data. To all this compar-
ison, we used the same PS-NPs as used in our previous
in vitro studies (Walczak et al. 2014).
In these previous in vitro studies, we developed an
integrated in vitro gastrointestinal digestion and
in vitro intestinal epithelium model as a screening
tool for assessing the translocation efficiency of orally
administered PS-NPs. The translocation of these PS-
NPs ranged from 1.6 to 12.3 % (Walczak et al. 2015).
Furthermore, these results indicated that the translo-
cation rate of the PS-NPs was affected by at least three
factors: (i) the physicochemical properties of the PS-
NPs (i.e. size and surface chemistry) (Walczak et al.
2014), (ii) the environmental conditions that the PS-
NPs were exposed to (i.e. incubation in an in vitro
gastrointestinal digestion model) (Walczak et al.
2015) and (iii) the properties of the in vitro monolayer
simulating the intestinal epithelium (i.e. presence of
mucus) (Walczak et al. 2014). Effects of size, surface
chemistry and the properties of the in vitro monolayer
on PS-NP translocation have also been reported by
others (Hussain et al. 2001; Szentkuti 1997; des Rieux
et al. 2005; Fazlollahi et al. 2011; Mahler et al. 2012).
In order to reduce the undesirable use of animals in
the evaluation of uptake of surface-modified NPs
(Hartung et al. 2013), alternative in vitro intestinal
translocation models need to be developed. However,
before such in vitro models can be used in a risk
assessment of NPs, they need to be validated (Kan-
darova and Letasiova 2011; Worth and Balls 2004)
using in vivo data (Genschow et al. 2002). As
mentioned earlier, the aim of this study was to assess
to which extent our in vitro model (combination of a
gastrointestinal digestion model and an intestinal
epithelium translocation model) predicts the translo-
cation efficiency occurring in vivo. To that end, rats
were orally exposed to a single dose of the same PS-
NPs as used in previous in vitro studies [i.e. neutral,
positive and negative, the latter from two different
suppliers with different surface modifications (Wal-




‘‘Neutral’’, amine- and carboxyl-modified 50 nm PS-
NPs [referred to as 50 (0), 50 (?), 50 (-M)] with a red
fluorophore core (Ex/Em: 530/590) were purchased
from Magsphere (Pasadena, CA, USA). Carboxyl-
modified 50 nm PS-NPs (referred to as 50 (-P)) with a
yellow-green fluorophore core (Ex/Em: 485/530) were
purchased from Polysciences (Warrington, Pennsyl-
vania, USA). PS-NPs were washed prior to adminis-
tration by centrifugation for 5 h at 18,0009g, 15 C
and re-suspension in deionised water, in order to
remove preservatives and surfactants present in the
suspension solution. The final mass concentration of
all stock suspensions was 2.5 %. Throughout this
paper, we have chosen to use the manufacturer
indication to identify the different types of NPs.
NP characterization
The NPs, as purchased, were characterized previously
(Walczak et al. 2014) using Scanning Electron
Microscopy (SEM), Dynamic Light Scattering
(DLS) and zeta potential measurements. To confirm
the size of the PS-NPs as administered to animals (i.e.
following washing and re-suspension in deionised
water), hydrodynamic sizes were again determined
using DLS. The measurements were performed as
previously described (Walczak et al. 2012). Suspen-
sions of 100 lg/ml were analysed in triplicate, and the
results are presented as the mean ± SD.
Stability of the fluorescent dye in PS-NPs
during exposure
No detectable leakage of the fluorescent dye from the
used PS-NPs was shown upon incubation under
simulated gastric digestion conditions. For this, PS-
NPs were incubated in simulated gastric juice for 2 h
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at 37 C, after which the suspensions were brought to
neutral pH and suspensions at 250 lg/ml were
centrifuged (30 min, 30009g, 20 C) in filter tubes
(Amicon Ultra-4 3 kDa Ultracel-PL memb 24/Pk;
Millipore BV, Netherlands). The filtrates were then
analysed for fluorescence.
Animal experiment
Five-week-old male Fischer 344 rats with a body
weight of 107 ± 8 g (upon arrival) were obtained
from Harlan (Horst, The Netherlands). Upon arrival,
rats were left to acclimatise for three weeks in groups
of two under standard conditions of humidity
(55–65 %), temperature (22 ± 3 C) and light (12-h
light/12-h dark cycles), with ad libitum access to feed
pellets (Abdiets, Woerden, The Netherlands) and tap
water. After 3 weeks, 25 rats were divided into five
groups (n = 5) for the experiment, based on their
weight to have a similar weight distribution in each
group (201 ± 13 g). Before treatment, rats were
fasted for 2 h. A single dose of 1 ml PS-NP suspension
per 200 g bw was administered through oral gavage at
a concentration of 25 mg/ml (resulting in a dose of
125 mg/kg bw). Rats in the control group received the
same volume of vehicle solution (i.e. deionised water)
only. The dose of 125 mg/kg bw was selected as this
was the highest achievable dose with these NPs. We
selected this rather high dose to increase the likelihood
of generating detectable amounts of NPs in tissues
given the expected low uptake in rats. After admin-
istration, rats were housed separately until the end of
the experiment. All animal experiments were ap-
proved by the ethical committee on animal experimen-
tation of Wageningen University & Research centre,
The Netherlands.
Blood samples (around 100 ll) were withdrawn
from the tail vein at time points: 0, 0.5, 1, 2 and 4 h and
collected in heparinized tubes. At t = 6 h, rats were
sacrificed under anaesthesia, and blood was collected
from the aorta, after which liver, kidneys, spleen,
lungs, heart, testis, brain, stomach, small intestine and
large intestine were collected. Previous studies indi-
cated that 6 h after an oral administration of NPs, their
plasma levels were declined (Lee et al. 2012; Bhat-
tacharjee et al. 2013). In addition, after 6 h the
administered bolus has passed the small intestine
(Fallingborg et al. 1989; Durmus-Altun et al. 2011).
Food remainders and faecal contents were gently
removed from the stomach and small- and large
intestines with a spoon, and the tissues were subse-
quently rinsed in PBS, to remove any unabsorbed PS-
NPs. The organs were weighed and divided into two
pieces for fluorescent and histopathological evalua-
tion. The pieces meant for fluorescence measurements
were preserved on ice, and the pieces meant for
histopathology/microscopic observations were pre-
served in Bouin solution (testis) or in 10 % neutral
buffered formalin (all other organs).
Fluorescence measurements of blood and organs
Harvested tissue samples (organs and blood) were
digested using an aqueous enzyme solution containing
1 g/l proteinase K (Sigma-Aldrich, St. Louis, MP,
USA) in 50 mM NH4HCO3 buffer (to maintain a
constant pH value of 7.4 during enzymatic digestion)
and 5 g/l SDS to improve activity of the enzyme
(Loeschner et al. 2013). Organs were carefully
weighed, cut into pieces and digested in digestion
buffer at a weight ratio of 1:5. The samples were
thoroughly vortexed and incubated at 37 C under
continuous stirring on a magnetic stirrer for 4 h. This
resulted in slightly turbid but homogenous suspen-
sions. Fluorescence of the samples was measured
using a SpectraMax M2 microplate reader (Molecular
Devices, Berkshire, UK) at excitation/emission wave-
lengths of 530/590 nm and 470/520 nm, for red and
yellow-green PS-NPs, respectively. The PS-NP con-
centration was determined based on previously pre-
pared standard calibration curves in each organ
separately, obtained by spiking blank organ ho-
mogenates (prepared as described above) with serial
dilutions of PS-NPs ranging from 0 to 20 lg/ml (for
organs) and 0–80 lg/ml (for blood). Calibration
curves were slightly non-linear at very low concen-
trations. For blood samples, calibration curves were
linear from NP concentrations of 5 lg/ml (for 50 nm
(0) and 50 nm (-M) NPs) and 1 lg/ml for the other
NPs. For other tissue samples, calibration curves were
linear from the NP concentrations of 1 lg/ml. Above
this concentration, calibration curves were linear for
all tissue samples, except for the kidney-derived
samples, but amounts of NPs in organs could be
derived in all cases. The PS-NP bioavailability was
estimated by summing up the amounts of NPs
measured in all tested organs except for the brain,
stomach wall and small- and large intestinal walls. For
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this, the amounts of NPs per gram tissue were
multiplied by the weights of the organs.
Histopathology
Samples for histopathology, fixed in 10 % formalin or
Bouin solution, were dehydrated in a series of ethanol
and embedded in paraffin. Approximately 5-lm-thick
sections were cut, mounted on glass slides and stained
with hematoxylin and eosin (H&E). The sections were
observed under an optical microscope (Zeiss, Cam-
bridge, UK) at different magnifications.
Fluorescence imaging
Intact livers, kidneys, spleens, lungs, testes, small
intestinal wall and large intestinal wall were scanned
for fluorescence with a fluorescence imager (Cellav-
ista V3.1, SynenTec Bio Services GmbH, Mu¨nster,
Germany) using illumination at wavelengths Ex/
Em = 470/520 nm or 530/590 nm, for yellow-green
(-P) PS-NPs and red (0, ?, -M) PS-NPs,
respectively.
Statistics
Data were analysed with SPSS (IBM, Version 21), and
the charts were generated with Prism software (v5.02;
GraphPad Software, Inc., La Jolla, USA). A one-way
analysis of variance ANOVA test and post hoc Tukey




The PS-NPs with different surface modifications were
characterized in water using SEM and zeta potential
measurements as reported previously (Walczak et al.
2014). Briefly, all types of 50 nm PS-NPs had similar
size distributions (as measured with SEM in stock
suspensions) with an average size of 31.6–35.0 nm,
except for the 50 nm (?) PS-NPs, which had a larger
average size of 50.6 nm (Table 1). The zeta potential
measurements in stock suspensions of the 50 nm (?)
and 50 nm (-) PS-NPs in water confirmed their
positive and negative charges (Table 1). The two types
of negatively charged 50 nm PS-NPs (-M and –P)
had the same zeta potential (i.e. -27.7 and
-27.8 mV), while the zeta potential of the positively
charged PS-NPs was 26.6 mV. The neutral PS-NPs
had a negative charge of-26.0 mV in water. The size
of PS-NPs re-suspended in deionised water, as
administered to animals, was measured with DLS.
The PS-NPs were monodispersed, and their hydrody-
namic diameters ranged from 50.0 ± 0 to
54.3 ± 0.1 nm (Table 1).
Fluorescence measurements of blood and organs
Fluorescence of the collected blood and organs was
determined. The concentration of the 50 nm (-P) PS-
NPs was high enough for detection in the kidney and
small- and large intestinal walls at the appropriate
wavelength using fluorescent microscopy, and the
concentrations of the 50 nm (0), (?) and (-M) PS-
NPs were high enough for detection in the small- and
large intestinal walls only (Fig. 1a–c). The fluores-
cence intensity could not be quantified reliably using
whole organs. Therefore, fluorescence intensity was
quantified using enzymatically digested organ ho-
mogenates, and PS-NP organ concentrations were
determined based on standard calibration curves made
in each organ. The PS-NP concentrations in the
different organs are shown in Fig. 2. Each of the four
types of PS-NPs induced a significant increase of
fluorescence in at least one of the tested organs,
indicating the passage of these PS-NPs through the
intestinal wall. In animals exposed to 50 nm (-P) PS-
NPs, the concentration of these PS-NPs was sig-
nificantly increased in kidney (p\ 0.05), spleen
(p\ 0.05), testis (p\ 0.01), heart (p\ 0.05), stom-
ach wall (p\ 0.000), small intestinal wall (p\ 0.01)
and large intestinal wall (p\ 0.05). In animals
exposed to 50 nm (?) PS-NPs, the concentration of
these PS-NPs was significantly increased in kidney
(p\ 0.1), spleen (p\ 0.01), testis (p\ 0.01), lung
(p\ 0.1), heart (p\ 0.1), stomach wall (p\ 0.1),
small intestinal wall (p\ 0.01) and large intestinal
wall (p\ 0.01). The concentrations of 50 nm (0) and
(-M) PS-NPs in the organs were considerably lower
than those of 50 nm (-P) and (?) PS-NPs, and they
reached significance only in few organs. In the animals
exposed to 50 nm (0) PS-NPs, the concentration of
these PS-NPs was significantly increased in spleen
(p\ 0.05), lung (p\ 0.1), small intestinal wall
231 Page 4 of 13 J Nanopart Res (2015) 17:231
123
(p\ 0.05) and large intestinal wall (p\ 0.01). The
concentration of 50 nm (-M) PS-NPs was significant-
ly increased in kidney (p\ 0.05), stomach wall
(p\ 0.05), small intestinal wall (p\ 0.05) and large
intestinal wall (p\ 0.05). No PS-NPs were detected in
blood samples from any time point.
In some organs, the PS-NP concentration was
significantly different between the different types of
PS-NPs, depending on their surface modifications. In
kidney, the concentration of 50 nm (-P) PS-NPs was
significantly higher than that of the 50 nm (?)
(p\ 0.05) and 50 nm (0) PS-NPs (p\ 0.05). Also
in heart, the concentration of 50 nm (-P) PS-NPs was
significantly higher than that of 50 nm (?) (p\ 0.05),
50 nm (0) (p\ 0.05) and 50 nm (-M) PS-NPs
(p\ 0.01). In the stomach wall, the concentration of
50 nm (-P) PS-NPs was significantly higher than that
of 50 nm (?) (p\ 0.1), and in the small intestinal wall
the concentration of 50 nm (-P) PS-NPs was sig-
nificantly higher than that of 50 nm (?) (p\ 0.05),
50 nm (0) (p\ 0.1) and 50 nm (-M) PS-NPs
(p\ 0.1).
The overall bioavailability of PS-NPs was estimat-
ed by summing up the amounts of PS-NPs in all
measured organs, except the stomach wall and
intestinal walls, as PS-NPs present in these organs
were most likely the result of direct absorption rather
than from uptake from the blood, and except the brain,
due to the selectivity of the blood–brain barrier. As
shown in Fig. 3, the resulting amount of PS-NPs as a
percentage of the administered dose was as low as 0.3
and 0.2 % for 50 nm (0) and (?) PS-NPs, respective-
ly, while the (-M) and (-P) PS-NPs reached
bioavailable levels of 1.5 and 1.7 %, respectively.
Due to the large variability in the (-M) and (-P)
groups, the higher estimated bioavailabilities of these
PS-NPs are not significantly different (p = 0.2) from
the estimated bioavailabilities of the (0) and (?) PS-
NPs.
Microscopic observations of tissue slides did not
reveal any histopathological changes.
Discussion
In the present study, we evaluated the bioavailability
and biodistribution of differently charged PS-NPs in
rats after a single oral administration. Our results show
the bioavailability and biodistribution of PS-NPs from
the gastrointestinal tract to different organs within 6 h.
The highest amounts of PS-NPs were measured in the
stomach- and intestinal walls. PS-NPs were detected
also in lung, testis, spleen, kidney and heart, meaning
that the PS-NPs were systemically available. Howev-
er, the overall estimated bioavailability was low,
ranging from 0.2 to 1.7 % of the administered dose.
All types of PS-NPs used in our study had the same
size, yet the organ uptake and distribution pattern was
different. This shows that the surface charge and
chemistry of PS-NPs affected their bioavailability to
the organs, as reported before for PS-NPs (Hillery and
Florence 1996; Hussain et al. 1997; Jani et al. 1989)
and other types of NPs (El-Shabouri 2002; Xiao et al.
2011).
Irrespective of surface charge, all types of PS-NPs
were measured in significant amounts in the small- and
large intestinal walls, as shown by fluorescence
measurements and organ imaging. The intestinal wall
Table 1 Physicochemical characterization of 50 nm PS-NPs
PS-NPs SEMa (nm) DLSb (nm) Zeta potentialc (mV)
50 nm (0) 33.4 ± 12.7 50.0 ± 0.0 -26.0 ± 16.2
50 nm (?) 50.6 ± 9.3 50.3 ± 0.4 26.6 ± 13.9
50 nm (-M) 35.0 ± 15.3 52.7 ± 2.4 -27.7 ± 19.3
50 nm (-P) 31.6 ± 13.6 54.3 ± 0.1 -27.8 ± 17.4
(0) neutral PS-NPs, (?) positively charged PS-NPs, (-M) and (-P) negatively charged PS-NPs from Magsphere and Polysciences,
respectively. Data in superscripts a and c from Walczak et al. (2014)
a Diameters (nm) of PS-NPs in water, as measured with SEM in stock suspensions (n = 80–380)
b Hydrodynamic diameters (nm) of PS-NPs in water, as determined by DLS at t = 0 h, after re-suspending the PS-NPs in deionised
water
c Zeta potential (mV) of PS-NPs in water, as determined by a zeta-sizer in stock suspensions at t = 0 h
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has been shown before to be the main site of
biodistribution for PS-NPs after oral administration
(Hussain et al. 1997; Jani et al. 1992). High levels of
PS-NPs measured in intestinal walls in our study could
be related with the uptake of PS-NPs in lymphoid
tissue associated with these organs, as shown before
(Florence et al. 1995; Hillery et al. 1994; Seifert et al.
1996). Also testis, spleen, kidney and heart had
considerably high concentrations of PS-NPs, irrespec-
tive of the type of administered PS-NPs. These organs,
and additionally also liver, have been shown before to
be the main organs where PS-NPs (Hussain et al. 1997;
Jani et al. 1990) and other types of NPs (Baek et al.
2012; Cho et al. 2013; van der Zande et al. 2012) were
distributed after being taken up into systemic circu-
lation after an oral exposure. Strikingly, the liver
showed no significant increase in fluorescence above
background levels, for any of the used NP types. After
sample treatment, all samples still were slightly turbid,
which could have distorted the fluorescent signal from
these samples potentially resulting in an increased
detection limit (Lakowicz 2007). Alternative expla-
nations for the lack of detectable amounts of NPs
could be related to the size of the PS-NP. It has been
shown that, while liposome NPs smaller than 70 nm
accumulated in liver, liposome NPs larger than
Fig. 1 Whole-organ fluorescence following a single oral
administration of 125 mg/kg bw PS-NPs. Pictures of kidney
(a), small- (b) and large intestinal walls (c) at t = 6 h showing
fluorescence under the illumination with wavelengths Ex/
Em = 470/520 nm or 530/590 nm, for yellow-green (-P) PS-
NPs and red (0, ?, -M) PS-NPs, respectively. Control organs
were collected from animals treated with only water. (0) neutral
PS-NPs, (?) positively charged PS-NPs, (-M) and (-P)
negatively charged PS-NPs from Magsphere and Polysciences,
respectively. (Color figure online)

















































































































Fig. 2 Organ distribution of 50 nm PS-NPs after 6 h from a
single oral exposure (125 mg/kg bw), expressed as lg PS-NPs/g
tissue, detected in organs from exposed animals. n.d. not
detectable, (0), (-M) and (-P) negatively charged PS-NPs from
Magsphere and Polysciences, respectively. Error bars show the
standard error of mean (n = 5). Significant difference between
the blank and exposed organs is illustrated as *p\ 0.1;
**p\ 0.05; ***p\ 0.01. Significant difference between dif-
ferent types of PS-NPs is illustrated as #p\ 0.1; ##p\ 0.05;
####p\ 0.01)
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200 nm accumulated in spleen (Liu et al. 1992). The
PS-NPs used in the present study could possibly
agglomerate during the passage through the gastroin-
testinal tract and as a result become larger than 70 nm.
Also another study performed with 50 nm PS-NPs has
shown the absence of the NPs in liver after 6 h from a
single oral exposure (Jani et al. 1992). Neither PS-NPs
were detected in blood at any time point, even with the
intervals of half an hour, most likely due to a rapid
transport of PS-NPs from the blood circulation to the
organs, as shown before (Fabian et al. 2008; Lankveld
et al. 2010; Geraets et al. 2014).
Several in vivo oral studies have been performed
before with different types of PS-NPs. Table 2 sum-
marizes oral studies performed in rats with different
sized and coated PS-NPs. The results from these
studies highlight the dependence of uptake and
accumulation of PS-NPs on several factors, including
the size, surface charge and type of coating material
(Araujo et al. 1999; Hillery et al. 1994; Hillyer and
Albrecht 2001; Hussain and Florence 1998; Hussain
et al. 1997; Jani et al. 1989). In general, smaller PS-
NPs were taken up to a higher extent than the larger
ones (Jani et al. 1990), the non-ionized more than the
carboxylated ones (Jani et al. 1989) and 407 polox-
amer-coated more than 188 poloxamer-coated across
the GI tract (Hillery and Florence 1996; Hussain et al.
1997).
The estimated oral bioavailability that we report
here (i.e. 0.2–1.7 %) is lower than that in a previous
oral study using 50 nm PS-NPs, where 6.6 %
estimated total uptake was reported (Jani et al.
1990) (Table 2). Also the amounts of PS-NPs
associated with intestinal tissues that we detected
(ranging between 0.38 and 0.74 % depending on the
type of PS-NPs, calculated as the sum of the small-
and large intestinal walls, data not shown) were
lower than the ones reported by others for 60 nm
PS-NPs, which varied between 1.5 and 10 %,
depending on the type of PS-NPs used (Hillery
and Florence 1996; Hillery et al. 1994). The
difference between data from the present study and
those of other in vivo studies might be due to the
use of different exposure conditions, as we exposed
the rats for 6 h, while in the previous studies the rats
were exposed for 5 or 10 days. Furthermore, the
bioavailability values given here were estimated
from the amounts of PS-NPs that were measured in
a selection of organs and therefore can be underes-
timated. The differences in the described amounts of
NPs that pass the intestinal walls could be further
caused by differences in tissue sampling methods
and methods of quantifying the concentration of PS-
NPs in tissues, and by large interindividual differ-
ences as shown before after intraduodenal adminis-
tration of PS-NPs, where the numbers of particles
subsequently found in lymph ducts varied consider-
ably between the different animals (Seifert et al.
1996). However, the amount of 50 nm (-P) PS-NPs
that was detected in kidney (0.3 %) was similar to
the 0.2 % reported by others for 50 nm PS-NPs
(Jani et al. 1990). Comparison of our results from
50 nm (-P) PS-NP to 300 nm PS-NPs in another
study shows that the amount of the 50 nm (-P) PS-
NPs that we detected in the liver (1.3 %), spleen
(0.07 %) and stomach wall (0.54 %) was similar to
the 1.4, 0.2 and 0.5 % reported for the liver, spleen
and stomach wall of 300 nm PS-NP-treated animals,
respectively (Jani et al. 1990). Furthermore, the
amount of PS-NPs we detected in the heart (0.17 %)
was largely similar to the 0.3 % detected for
500 nm PS-NPs (Hussain et al. 1997). However,
our bioavailability values are lower than the ex-
trapolated 23 % that was reported for much larger



































Fig. 3 Estimated bioavailability of 50 nm PS-NPs, expressed
as a percentage of the administered dose (125 mg/kg bw),
calculated by summing up the amounts of PS-NPs detected in all
analysed organs, except the stomach- and intestinal walls and
brain. (0) neutral PS-NPs, (?) positively charged PS-NPs,
(-M) and (-P) negatively charged PS-NPs from Magsphere
and Polysciences, respectively. Error bars show the standard
error of mean (n = 5)
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PS-NPs of 1 lm had a lower uptake than what we
report here [2 9 10-6 % of 1 lm PS-NPs detected
in lymph fluid (Seifert et al. 1996)].
Comparison of the bioavailability values ranging
between 0.2 and 1.7 % that we report here, with the
translocation values of the same 50 nm PS-NPs in our
integrated in vitro digestion and in vitro intestinal
model, which ranged from 1.6 to 12.3 % (Walczak
et al. 2015), shows lower uptake values in the in vivo
model (Table 3). However, a direct comparison
should only be performed with caution as the used
exposure times in the in vitro and in vivo exposures
were different (24 h in vitro and for the in vivo study
samples were collected 6 h after administration). In
addition, the administered doses used were different.
Future kinetic modelling could aid in comparing the
results from these experiments. Also the relative order
of translocation in vitro (Walczak et al. 2014, 2015)
differed from the order of uptake of PS-NPs in vivo.
However, the 50 nm (-P) PS-NPs, which translocated
to the largest extent in vitro, were also taken up to the
largest extent in the present in vivo study, as shown in
organs where the PS-NPs concentrations were the
highest (i.e. in kidney and heart).
Conclusion
Our results show that the predicted uptake of PS-NPs
from our integrated in vitro model appears to overes-
timate the actual uptake occurring in the rat in vivo.
Therefore, the in vitro model cannot be used for a
direct prediction of bioavailability of orally adminis-
tered PS-NPs in a rat model. However, our model can
be used for screening and prioritizing NPs before
further in vivo testing for risk assessment and for drug
delivery efficacy. Similar to in vitro results, the surface
charge and surface chemistry affected the uptake and
biodistribution of 50 nm PS-NPs after oral exposure in
rats. The negatively charged PS-NPs were present in
almost all organs to a much higher extent than the
neutral and positively charged PS-NPs, which is in line
with the in vitro translocation data of these PS-NPs.
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